Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-21
2010-11-16
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07834201
ABSTRACT:
The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.
REFERENCES:
patent: 4943590 (1990-07-01), Boegesoe et al.
patent: RE34712 (1994-08-01), Boegesoe et al.
patent: 5607697 (1997-03-01), Alkire et al.
patent: 2004/0167209 (2004-08-01), Dancer et al.
patent: 2003282383 (2005-06-01), None
patent: 2007303 (1970-09-01), None
patent: 2 657 013 (1977-07-01), None
patent: 60202216 (2003-01-01), None
patent: 60217932 (2005-04-01), None
patent: 60202794 (2006-05-01), None
patent: 0347066 (1989-12-01), None
patent: 1120120 (2001-08-01), None
patent: 1346989 (2003-09-01), None
patent: 1366760 (2003-12-01), None
patent: 10-298061 (1998-11-01), None
patent: 2000-178204 (2000-06-01), None
patent: 2002316923 (2002-10-01), None
patent: 2003519121 (2003-06-01), None
patent: 2003527383 (2003-09-01), None
patent: 2004536093 (2004-12-01), None
patent: WO-98/19512 (1998-05-01), None
patent: WO-98/19513 (1998-05-01), None
patent: WO-99/00548 (1999-01-01), None
patent: WO-00/11926 (2000-03-01), None
patent: WO-00/13648 (2000-03-01), None
patent: WO-0108619 (2001-02-01), None
patent: WO-01/47877 (2001-07-01), None
patent: WO-0147877 (2001-07-01), None
patent: WO-01/68627 (2001-09-01), None
patent: WO-0168627 (2001-09-01), None
patent: WO-0180619 (2001-11-01), None
patent: WO-03/000672 (2003-01-01), None
patent: WO-03/006449 (2003-01-01), None
patent: WO-03/011278 (2003-02-01), None
patent: WO-03039520 (2003-05-01), None
patent: WO-03/051861 (2003-06-01), None
patent: 03/092659 (2003-11-01), None
patent: WO-2004/056791 (2004-07-01), None
patent: WO-2005/018617 (2005-03-01), None
patent: WO-2005049596 (2005-06-01), None
patent: WO-2006/106531 (2006-10-01), None
Partial International Search Report dated Jan. 16, 2007 issued for corresponding International Patent Application No. PCT/DK2006/000366.
P. Molander et al., Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2002), 766(1), (77-87) discloses citalopram N-oxide (p. 79, col. A, first paragraph, lin 10).
Rampono et al., “Citalopram and demethylcitalopram in human milk; distriburtion, excretion and effects in breast fed infants,” Br. J. Clin. Pharmacol., 2000, 50:263-268.
Comments of plaintiff Teva Phamaceuticals CR, s.r.o. dated Aug. 30, 2010, filed in opposition proceedings to counterpart patent, CZ Patent No. 299,906, 5 pages.
Comments of plaintiff Zentiva, k.s. dated Aug. 30, 2010, filed in opposition proceedings to counterpart patent, CZ Patent No. 299 906, 5 pages.
Dancer Robert
Eliasen Helle
Liljegren Ken
Nielsen Ole
Petersen Hans
Chandrakumar Nizal S
Fish & Richardson P.C.
H. Lundbeck A/S
Seaman D. Margaret
LandOfFree
Crystalline base of escitalopram and orodispersible tablets... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline base of escitalopram and orodispersible tablets..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline base of escitalopram and orodispersible tablets... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4228923